论文部分内容阅读
目的 观察丙型肝炎病毒 (HCV)核心 (C)基因DNA疫苗在体内对小鼠HCV皮下移植瘤的治疗作用及白细胞介素 12 (IL 12 )对其的增强效果。方法 构建含HCVC基因片段的重组真核表达质粒 pcDNAHCV C ,用脂质体Lipofectamine法将其转染小鼠骨髓瘤SP2 / 0 (H 2 d)细胞 ,经G418筛选获稳定表达HCVC抗原之后 ,以 5× 10 5个细胞 / 10 0 μl,注射Balb/c小鼠右肋皮下 ,3d后2 0只实验小鼠分成 3组 ,即 :空载体 pcDNA3 对照组、pcDNAHCV C治疗组和pcDNAHCV C +IL 12表达质粒治疗组。观察并记录成瘤时间、肿瘤大小及小鼠存活时间。结果 重组质粒 pcDNAHCV C治疗组 ,使SP2 / 0 HCV C细胞成瘤性显著降低 ,对HCV皮下移植瘤有一定的治疗作用 ;与表达IL 12质粒联合接种后 ,治疗作用加强。结论 佐以合适的细胞因子 ,有可能提高DNA疫苗的治疗作用
Objective To observe the therapeutic effect of hepatitis C virus (HCV) core (C) DNA vaccine on mice subcutaneously transplanted with HCV and enhance its effect by interleukin 12 (IL 12). Methods The recombinant eukaryotic expression plasmid pcDNAHCV C containing HCVC gene fragment was constructed and transfected into mouse myeloma SP2 / 0 (H 2 d) cells by Lipofectamine method. After stable expression of HCVC antigen by G418, 5 × 10 5 cells / 100 μL. Twenty Balb / c mice were injected subcutaneouly into the right flank. After 3 days, 20 mice were divided into 3 groups: empty vector pcDNA3 control group, pcDNAHCV C treatment group and pcDNAHCV C + IL 12 expression plasmid treatment group. Observe and record the tumor formation time, tumor size and survival time of mice. Results The recombinant plasmid pcDNAHCV C treatment group significantly decreased the tumorigenicity of SP2 / 0 HCV C cells and had a certain therapeutic effect on the subcutaneous xenografts of HCV. The combination therapy with IL 12 plasmid enhanced the therapeutic effect. Conclusion Adjusted with appropriate cytokines, it is possible to improve the therapeutic effect of DNA vaccine